


Neuroglia



mdpi.com/ journal/ neuroglia



Message from the Editor-in-Chief

Neuroglia covers the critically important functions of the diverse range of cells within the nervous system that are collectively called glia. Our journal focuses on the development, function, and pathology of glia in the central and peripheral nervous systems, as well as how these cells can be used therapeutically to repair injuries and diseases of the nervous system. The journal welcomes research using the latest in vitro and in vivo animal and human research, with a view to its translation into potential human therapies.

Editor-in-Chief

Prof. Dr. Jessica Filosa

Aims

Neuroglia (ISSN 2571-6980) is a peerreviewed open access journal that provides an advanced forum for studies on neuroglia. The journal publishes reviews, regular research papers, short communications, conference reports, and commentaries. We encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the maximum length of papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the neuroglial cell community. Highlights from the recent developments will also be featured in the 'News and Views' section.

Neuroglia aims to establish a platform for glial neuropathology and the glial role in neurological diseases in animal models and humans.

Scope

Neuroglia is a peer-reviewed multidisciplinary open access journal that aims to disseminate research on the numerous roles of glial cells in maintaining and repairing nervous system function.

Neuroglia welcomes submissions on the morphology, function, and pathology of glia in the central and peripheral nervous systems. The journal covers all aspects of glial functions in development, adulthood, and diseases as well as injuries. Studies addressing advancements in glia biology, including animal or in vitro models with translational potential for human therapies, are welcome.

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Rapid Publication

A first decision is provided to authors approximately 21.8 days after submission; acceptance to publication is undertaken in 6.3 days (median values for papers published in this journal in the second half of 2024)

MDPI is a member of





















ORCID



Editorial Office

neuroglia@mdpi.com

MDPI Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 mdpi.com January 2025

